Compounded PT-141 (Bremelanotide)
Check whether compounded PT-141 (Bremelanotide) can be routed, what restrictions may apply, and what to ask your prescriber or pharmacist.
About PT-141 (Bremelanotide)
Important: PT-141 (Bremelanotide) is not currently eligible for compounding by licensed U.S. pharmacies due to FDA restrictions. Quote requests for PT-141 cannot be fulfilled through Compounding Finder.
Key Questions Before You Request Quotes
Can I get PT-141 (Bremelanotide) compounded?
Not through Compounding Finder right now. A prescriber and pharmacist still have to decide whether any compounded PT-141 (Bremelanotide) preparation is legally and clinically appropriate.
Is a prescription needed?
Yes. Patient-specific 503A compounding is based on a valid prescription order or prescriber notation for an identified patient.
What affects price?
Strength, dosage form, quantity, ingredient sourcing, sterile versus non-sterile preparation, shipping requirements, and each pharmacy's workflow can all change the final quote.
How fast can I get quotes?
For routable requests, Compounding Finder typically returns quote options by email within 1-2 business days after you submit the request details.
What happens after I submit?
We review the request, route it to eligible licensed pharmacies, collect available options, and email you the quoted choices. You decide whether to move forward with a pharmacy.
Source notes: FDA explains that compounded drugs are not FDA-approved finished products and describes 503A compounding around patient-specific prescriptions. See Compounding and the FDA and Section 503A.
We Do Not Currently Route PT-141 (Bremelanotide) Quote Requests
PT-141 / bremelanotide is not on the FDA 503A bulk substances list for generic compounding. The brand-name product Vyleesi is FDA-approved for a specific indication — talk to your prescriber about whether that is an option. If FDA guidance changes, we will revisit.
What patients use instead of compounded PT-141
Bremelanotide — the active molecule in PT-141 — is available as an FDA-approved prescription product under the brand name Vyleesi. It is approved only for hypoactive sexual desire disorder (HSDD) in premenopausal women and must be prescribed by a licensed clinician.
- Vyleesi (bremelanotide)FDA-approved
Same active molecule as PT-141, prepared and FDA-approved as a pre-filled subcutaneous autoinjector by Palatin Technologies. Approved for acquired, generalized HSDD in premenopausal women; used as-needed, not daily.
List price is high (~$900+/4 doses); patient support and commercial copay programs are available from the manufacturer.
Check Vyleesi pricing on GoodRx → - Addyi (flibanserin)FDA-approved
A different molecule from bremelanotide, but the other FDA-approved option for HSDD in premenopausal women. Oral, taken nightly. Worth discussing with your prescriber if Vyleesi is not a fit.
Check Addyi pricing on GoodRx → - Telehealth evaluation for HSDDGet a prescription
Several telehealth services have clinicians who can evaluate you for HSDD and prescribe Vyleesi or Addyi if appropriate. Ask whether women's sexual health is an area of their practice before booking.
Search women's health telehealth providers →
Links to external price-comparison tools and retail pharmacies are provided for convenience. Compounding Finder is not affiliated with these services and does not receive information about your purchases. Always consult your prescriber before changing medications.